Please wait a minute...
Shopping Cart Email List Chinese
Advanced Search Fig/Tab
Frontiers of Medicine

ISSN 2095-0217

ISSN 2095-0225(Online)

CN 11-5983/R

Postal Subscription Code 80-967

2018 Impact Factor: 1.847

Featured Articles  |  Most Downloaded  |  Most Reading
Online Submission Subscribe to Our RSS Content Feed
Front Med Chin    2009, Vol. 3 Issue (1) : 49-56    https://doi.org/10.1007/s11684-009-0012-y
RESEARCH ARTICLE
Gene expression disparity in giant cell tumor of bone
Xiaohua PAN1,2, Shuhua YANG1(), Deming XIAO2, Yong DAI3, Lili REN3
1. Department of Orthopaedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China; 2. Department of Orthopaedics, Shenzhen People’s Hospital, The Second Medical College of Jinan University, Shenzhen 518020, China; 3. Clinical Research Center, Shenzhen People’s Hospital, The Second Hospital Medical College of Jinan University, Shenzhen 518020, China
 Download: PDF(99 KB)   HTML
 Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Abstract

The aim of this paper was to study the differential gene expression of giant cell tumor of bone (GCTB) by gene chip technology. Total RNA of 8 fresh GCTB specimens (Jaffe I∶6 cases, II∶1 case, III∶1 case; Campanacci I∶6 cases, II∶1 case, III∶1 case; Enneking Staging G0T1-2M0: 5 cases, G1T1-2M0: 2 cases, G1T2M0: 1 case) and 4 normal bony callus specimens (the control group) were extracted and purified to get mRNA and then reverse transcribed to complementary DNA, respectively. Microarray screening with a set of 8064 human cDNA genes was conducted to analyze the difference among the samples and the control. The hybridization signals were scanned. The gene expression disparity between the GCTB samples and normal bony callus was significantly different (P<0.01), and the disparity of over 5-fold was found in 47 genes in the GCTB specimens, with 25 genes up-regulated and 22 down-regulated including the extracellular matrix and transforming-related genes, oncogene and its homolog genes, cytokine and its receptor genes. Specific gene spectrum associated with GCTB can be identified by cDNA microarray, which will be the foundation of progressive etiology elucidation, diagnosis and treatment of GCTB.
Keywords giant cell tumor of bone      gene      microarray, cDNA     
Corresponding Author(s): YANG Shuhua,Email:shuhuayabc@vip.sina.com   
Issue Date: 05 March 2009
 Cite this article:   
Shuhua YANG,Deming XIAO,Yong DAI, et al. Gene expression disparity in giant cell tumor of bone[J]. Front Med Chin, 2009, 3(1): 49-56.
 URL:  
https://academic.hep.com.cn/fmd/EN/10.1007/s11684-009-0012-y
https://academic.hep.com.cn/fmd/EN/Y2009/V3/I1/49
gene tagGenBankUniGenegene namerelated function
MMP13N69322Hs.2936matrix metalloproteinase 13participates in collagen catabolism, albuminolysis; collagen protease and metalloendoprotease activity
DSPG3AA131238Hs.435680dermatan sulphate mucoprotein 3regulates glycosaminoglycan binding
DPTR48303Hs.80552skin pontine proteincell adhesion and protein binding
MMP12R92994Hs.645661matrix metalloproteinase 12endometrium adenocarcinoma oncogene
COL3A1T98612Hs.443625type III collagen α1participates in formation of connective tissue like skin and pneumoangiogram, mutation leads to type IV Ehlers-Danlos syndrome
MMP9T72581Hs.297413matrix metalloproteinase 9increases expression on abdominal aortic aneurysm anterior wall
COL1A2AA490172Hs.489142type I collagen α2encodes a chain of type I collagen, variation may lead to osteogenesis imperfecta, Ehlers-Danlos syndrome, idiopathic osteoporosis, atypical arachnodactyly
COL8A2AA780815Hs.353001type VIII collagen α2endothelial corneal dystrophy related
COL5A2AA461456Hs.445827type V collagen α2encodes an α chain of low abundance collagen fiber, related with type I, II Ehlers-Danlos syndrome
CTSSAA236164Hs.181301cathepsin Sfamily of C1 peptidase of lysosome cysteine proteinase
MMP2AA936799Hs.513617matrix metalloproteinase 2encodes the degradation of type IV collage enzyme
COL5A3AA994760Hs.235368type V collagen α3encodes an α chain of low abundance collagen fiber, related with Ehlers-Danlos syndrome
Tab.1  Table 1a Formation and transition with extracellular matrix related differentially up-regulated expression genes (12 genes)
gene tagGenBankUniGenegene namerelated function
MMP3 W51794Hs.645710matrix metalloproteinase 3collagen catabolism and calcium, and zinc deposition
COMPN94385Hs.1584cartilage oligomer matrix proteincalcific deposit and extracellular matrix structure composition, participates in beta -TGF signal pathway, closely related with skeleton development, activity of structure molecule
COL10A1AI828306Hs.520339collagen of type α1Xdown-regulation will cause epiphysis dyschondroplasia, maldevelopment or dysplasia
MMP7AA031514Hs.2256matrix metalloproteinase 7degrades proteoglycans, fibronectin, elastin, casein and participates in wound healing
COL1A2AA490172Hs.489142type I collagen α2encodes a chain of type I collagen, variation may lead to osteogenesis imperfecta, Ehlers-Danlos syndrome, Idiopathic osteoporosis, atypical arachnodactyly
COL6A1H99676Hs.474053type VI collagen α1mutation may lead to autosomal dominant disorder: Bethlem myopathy
COL18A1N81029Hs.517356type XVIII collagen α1related with spinal injury
MMP15AA443300Hs.80343matrix metalloproteinase 15cell surface matrix metalloproteinase
Tab.2  Table 1b Formation and transition with extracellular matrix related differentially down-regulated expression genes (8 genes)
gene tagGenBankUniGenegene namerelated function
PTTG1AA430032Hs.350966hypophysin tumor transforming gene 1participates in DNA metabolism, repair, replication and chromosomal disjunction. affects RNA polymerase 2 activity
ERBB3AA664212Hs.118681ornithoerythroblast leukemia virus tumorigenesis gene 3participates in the calcium signal pathway, transmembrane receptor protein tyrosine kinase (PTK) signal pathway, related with ATP, membrane protein phosphorylation, epidermal growth factor (EGF) receptor
MNDAN29376Hs.153837bone marrow nucleus differentiation antigenparticipates in cell defence reaction and cell transcription regulation
PIM2AA863383Hs.496096pim-2 oncogenerelated to carcinoma of prostate; participates in NF-kappaB activation pathway, regulates cell survival
RB1AA045192Hs.408528retinal glioblastoma factor 1related to retinal glioblastoma, osteosarcoma
FGRAA256172Hs.1422proto-oncogene tyrosine protein kinase FGRtyrosine protein kinase Src family member, negatively regulates cell migration and adherence
Tab.3  Table 2a Up-regulated expression of tumor related genes (6 genes)
gene tagGenBankUniGenegene namerelated function
PTGESAA436163Hs.146688prostaglandin E synthaseparticipates in prostaglandin metabolism and signal transduction
TYRO3W69497Hs.381282protein tyrosine kinase (PTK)participates in protein binding, receptor activity and signal transduction, etc
HYAL1AA464196Hs.75619hyaluronic acid glucosaminidase 1participates in glucosaminidase, hydrolysis enzymatic activity somato-regulation; significant efficacy on glycon synthesis and lysosome receptor activity
ELF3AA434373Hs.67928E74 like factor 3affects formation of biphasic differentiation synovial sarcoma epithelium structure
MPP2R60019Hs.514208membrane protein,palmitoylation 2affects cytoskeleton, regulates cell proliferation and signal pathway
ERBB2AA446928Hs.446352erythroblast leukemia virus tumorigenic gene homologue 2one of the encoding epidermal growth factor receptor family, breast carcinoma, ovarian cancer
Tab.4  Table 2b Up-regulated expression of tumor related genes (6 genes)
gene tagGenBankUniGenegene namerelated function
SCYA3AA677522Hs.514107small inducible cytokine A3regulates calcium ion dynamic equilibrium and cell movement, chemotactic factor, exocytosis, inflammatory response, signal transducer
TNFRSF11BAA194983Hs.81791tumor necrosis factor receptor family 11Bparticipates in apoptosis and skeletal development
SCYA18AA495985Hs.143961small inducible cytokine A18immunoregulation, inflammatory response related secretory protein; participates in inflammatory response
SCYA3L1R47893Hs.512683small inducible A3 like cytokine 1related with macrophage inflammatory protein
SCYB6AI889554Hs.164021small inducible cytokine subunit B6participates in neovascularization, affects tumor formation
SCYA4H62864Hs.655293small inducible cytokine A4macrophage inflammatory protein 1, lymphocyte activation
Tab.5  Table 3a Differential up-regulatied expression of cytokine and receptor family related genes (6 genes)
gene tagGenBankUniGenegene namerelated function
SCYD1R66139Hs. 6376small inducible cytokine D1chemotactic factor (C-X3 ligand 1), participates in immune response and calcium ion dependent cell-cell adhesion
SCYB14W72294Hs.483444small inducible cytokine B14chemotactic factor (C-X3 ligand 14)
IFNGR1H11482Hs.520414γ interferon 1participates in many kinds of immune response and signal transduction
TNFAIP2AA457114Hs.660676tumor necrosis factor, α-induced protein 2retinoic acid of target gene in acute promyelocytic leukemia (APL)
LILRB2H54023Hs.655652leukocyte immunoglobulin like receptor Bcontrols inflammatory reaction and cytotoxicity to centralize immunological reaction; recognition of MHC molecule HLA-G
Tab.6  Table 3b Differentially up-regulatied expression of cytokine and receptor family genes (5 genes)
1 Tubbs W S, Brown L R, Beabout J W, Rock M G, Unni K K. Benign giant-cell tumor of bone with pulmonary metastases: clinical findings and radiologic appearance of metastases in 13 cases. AJR , 1992, 158(3): 331-334
2 Sung H W, Kuo D P, Shu W P, Chai Y B, Liu C C, Li S M. Giant-cell tumor of bone: analysis of two hundred and eight cases in Chinese patients. J Bone Joint Surg Am , 1982, 64(5): 755-761
3 Prosser G H, Baloch K G, Tillman R M, Carter S R, Grimer R J. Does curettage without adjuvant therapy provide low recurrence rates in giant-cell tumors of bone? Clin Orthop Relat Res , 2005, 435(6): 211-218
doi: 10.1097/01.blo.0000160024.06739.ff
4 Ladanyi M, Tragano F, Huvos A, Benign metastasizing giant cell tumours of bone. Cancer , 1989, 64(7): 1521-1526
doi: 10.1002/1097-0142(19891001)64:7&lt;1521::AID-CNCR2820640727&gt;3.0.CO;2-7
5 Tian B L, Wen J M, Zhang M, Xie D, Xu R B, Luo C J. The expression of ADAM12 (meltrin alpha) in human giant cell tumours of bone. Mol Pathol , 2002, 55(6): 394-397
doi: 10.1136/mp.55.6.394
6 Kumta S M, Huang L, Cheng Y Y, Chow L T C, Lee K M, Zheng M H. Expression of VEGF and MMP-9 in giant cell tumor of bone and other osteolytic lesions. Life Sci , 2003, 73(11): 1427-1436
doi: 10.1016/S0024-3205(03)00434-X
7 Welford S M, Gregg J, Chen E, Garrison D, Sorensen P H, Denny C T, Nelson S F. Detection of differentially expressed genes in primary tumor tissues using representational differences analysis coupled to microarray hybridization. Nucleic Acids Res , 1998, 26(12): 3059-3065
doi: 10.1093/nar/26.12.3059
8 Li D P, Wang K, Dai Y, LV T Y. Gene Expression Profiling on Acute Rejected Transplant Kidneys with Microarray. J Huazhong Univ Sci Technol (Med Sci) . 2008, 28(2): 136-139
9 Logar D B, Komadina R, Prezelj J, Ostanek B, Trost Z, Marc J. Expression of bone resorption genes in osteoarthritis and in osteoporosis. J Bone Miner Metab , 2007, 25(4): 219-225
doi: 10.1007/s00774-007-0753-0
10 Lacey D L, Timms E, Tan H L, Kelley M J, Dunstan C R, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian Y X, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle W J. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell , 1998, 93(2): 165-176
doi: 10.1016/S0092-8674(00)81569-X
11 Kong Y Y, Feige U, Sarosi I, Bolon B, Tafuri A, MoronyS, Capparelli C, Li J, Elliott R, McCabe S, Wong T, Campagnuolo G, Moran E, Bogoch E R, Van G, Nguyen L T, Ohashi P S, Lacey D L, Fish E, Boyle W J, Penninger J M. Activated T cells regulate bone loss and joint destuction in adjuvant arthritis through osteoprotegerin ligand. Nature , 1999, 402(6759): 304-309
doi: 10.1038/46303
12 Takayanagi H, Kim S, Matsuo K, Suzuki H, Suzuki T, Sato K, Yokochi T, Oda H, Nakamura K, Ida N, Wagner E F, Taniguchi T. RANKL maintaims bone homeostasis through c-Fos-dependent induction of interferon-beta.Nature ,2002, 418 (6882): 744-749
doi: 10.1038/416744a
13 Guenther R, Krenn V, Morawietz L, Dankof A, Melcher I, Schaser K D,KasperH U, Kuban R J, Ungethüm U, Sers C. Giant cell tumors of the bone: molecular profiling and expression analysis of Ephrin A1 receptor, Claudin 7, CD52, FGFR3 and AMFR. Pathol Res Pract , 2005, 201(10): 649-663
doi: 10.1016/j.prp.2005.07.005
14 Saiz P, Virkus W, Piasecki P, Templeton A, Shott S, Gitelis S. Results of giant cell tumor of bone treated with intralesional excision. Clin Orthop , 2004, 7(424): 221-226
doi: 10.1097/01.blo.0000128280.59965.e3
15 Lackman R D, Hosalkar H S, Ogilvie C M, Torbert J T, Fox E J. Intralesional curettage for grades II and III giant cell tumors of bone. Clin Orthop Relat Res , 2005, 438(9): 123-127
doi: 10.1097/01.blo.0000180051.27961.c3
16 Lausten G S, Jensen P K, Schi?dt T, Lund B. Local recurrences in giant cell tumour of bone: long-term follow up of 31 cases. Int Orthop , 1996, 20(3): 172-176
doi: 10.1007/s002640050057
17 Ghert M A, Rizzo M,HarrelsonJ M, Scully S P. Giant cell tumor in the appendicular skeleton, Clin Orthop Relat Res , 2002, 400(7): 201-210
doi: 10.1097/00003086-200207000-00025
[1] Ling Wang, Lining Wang, Xing Fan, Wei Tang, Jiong Hu. Fludarabine and intravenous busulfan conditioning with post-transplantation cyclophosphamide for allogeneic peripheral stem cell transplantation for adult patients with lymphoid malignancies: a prospective single-arm phase II study[J]. Front. Med., 2021, 15(1): 108-115.
[2] Jing Ma, Shiyu Chen, Lili Hao, Wei Sheng, Weicheng Chen, Xiaojing Ma, Bowen Zhang, Duan Ma, Guoying Huang. Long non-coding RNA SAP30-2:1 is downregulated in congenital heart disease and regulates cell proliferation by targeting HAND2[J]. Front. Med., 2021, 15(1): 91-100.
[3] Xiaowei Zhu, Houfeng Zheng. Factors influencing peak bone mass gain[J]. Front. Med., 2021, 15(1): 53-69.
[4] Xiaojing Jiao, Dong Zhang, Quan Hong, Lei Yan, Qiuxia Han, Fengmin Shao, Guangyan Cai, Xiangmei Chen, Hanyu Zhu. Netrin-1 works with UNC5B to regulate angiogenesis in diabetic kidney disease[J]. Front. Med., 2020, 14(3): 293-304.
[5] Amy Lee, Fa-Chyi Lee. Medical oncology management of advanced hepatocellular carcinoma 2019: a reality check[J]. Front. Med., 2020, 14(3): 273-283.
[6] Xuran Chu, Chengshui Chen, Chaolei Chen, Jin-San Zhang, Saverio Bellusci, Xiaokun Li. Evidence for lung repair and regeneration in humans: key stem cells and therapeutic functions of fibroblast growth factors[J]. Front. Med., 2020, 14(3): 262-272.
[7] Guangbiao Zhou, Saijuan Chen, Zhu Chen. Advances in COVID-19: the virus, the pathogenesis, and evidence-based control and therapeutic strategies[J]. Front. Med., 2020, 14(2): 117-125.
[8] Qiaoshuai Lan, Shuai Xia, Qian Wang, Wei Xu, Haiyan Huang, Shibo Jiang, Lu Lu. Development of oncolytic virotherapy: from genetic modification to combination therapy[J]. Front. Med., 2020, 14(2): 160-184.
[9] Jiahui Xu, Qianqian Wang, Elaine Lai Han Leung, Ying Li, Xingxing Fan, Qibiao Wu, Xiaojun Yao, Liang Liu. Compound C620-0696, a new potent inhibitor targeting BPTF, the chromatin-remodeling factor in non-small-cell lung cancer[J]. Front. Med., 2020, 14(1): 60-67.
[10] Rui Zhou, Yuanshu Liu, Wenjun Huang, Xitong Dang. Potential functions of esophageal cancer-related gene-4 in the cardiovascular system[J]. Front. Med., 2019, 13(6): 639-645.
[11] Xin Qin, Ping Zhang. ECRG4: a new potential target in precision medicine[J]. Front. Med., 2019, 13(5): 540-546.
[12] Xiao He, Chentao Jin, Mindi Ma, Rui Zhou, Shuang Wu, Haoying Huang, Yuting Li, Qiaozhen Chen, Mingrong Zhang, Hong Zhang, Mei Tian. PET imaging on neurofunctional changes after optogenetic stimulation in a rat model of panic disorder[J]. Front. Med., 2019, 13(5): 602-609.
[13] Haolin Sun, Chun Liu, Shunlun Chen, Yanjie Bai, Huilin Yang, Chunde Li, Lei Yang. Effect of surgical factors on the augmentation of cement- injectable cannulated pedicle screw fixation by a novel calcium phosphate-based nanocomposite[J]. Front. Med., 2019, 13(5): 590-601.
[14] Xin Wu, Xiaobao Sheng, Rong Sheng, Hongjuan Lu, Huji Xu. Genetic and clinical markers for predicting treatment responsiveness in rheumatoid arthritis[J]. Front. Med., 2019, 13(4): 411-419.
[15] Ning Jiang, Yao Li, Ting Shu, Jing Wang. Cytokines and inflammation in adipogenesis: an updated review[J]. Front. Med., 2019, 13(3): 314-329.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed